Introduction
Hidradenitis suppurativa is treated with a combination of medical therapy, procedures, and long-term disease management strategies. The main treatments include topical and oral antibiotics, anti-inflammatory medications, hormonal therapies in selected patients, biologic drugs that alter immune signaling, and surgical or procedural approaches such as drainage, laser therapy, and excision. These treatments are used because hidradenitis suppurativa is not a simple infection; it is a chronic inflammatory disorder in which hair follicle blockage, rupture, immune activation, and recurrent tissue damage drive the disease process. Treatment therefore aims not only to relieve pain and drainage, but also to interrupt the biological cycle that leads to persistent nodules, abscesses, sinus tracts, and scarring.
The condition typically develops in areas where skin rubs together and where terminal hair follicles are abundant, such as the axillae, groin, buttocks, and under the breasts. Repeated inflammation in these sites can damage the follicular unit and surrounding tissue, leading to chronic lesions. Effective treatment attempts to reduce this inflammatory activity, limit further structural damage, and preserve as much normal function as possible.
Understanding the Treatment Goals
The main goals of treatment are to reduce pain, swelling, and drainage; suppress the inflammatory process that sustains the disease; prevent new lesions from forming; and reduce the formation of tunnels and scarring. Because hidradenitis suppurativa often progresses from isolated inflamed nodules to interconnected sinus tracts and fibrotic scars, early treatment is directed at controlling inflammation before structural damage becomes established. Later-stage treatment often focuses more on removing or disabling damaged tissue and controlling chronic inflammation than on reversing fully formed lesions.
Treatment decisions are guided by the biological features of the disease. If inflammation appears to be the dominant process, therapies that alter immune signaling or bacterial burden may be chosen. If closed tunnels and scarred tissue are already present, medication alone is often insufficient because the abnormal tissue architecture can continue to support chronic drainage and recurrent inflammation. In that setting, procedures or surgery may be needed to change the local structure of the affected skin.
Common Medical Treatments
Topical antibiotics, especially clindamycin, are often used for mild disease. Their effect is not limited to killing bacteria. They also reduce local inflammatory signaling in the skin and can decrease the number of inflammatory lesions. In hidradenitis suppurativa, bacteria are not usually the primary cause, but bacterial colonization can amplify inflammation once follicles rupture and the skin barrier is disrupted. Topical treatment targets this local cycle with minimal systemic exposure.
Oral antibiotics are commonly used when disease is more widespread or persistent. Tetracyclines such as doxycycline and minocycline are used not only for their antimicrobial action but also because they suppress inflammatory pathways, including neutrophil activity and cytokine production. In hidradenitis suppurativa, this can reduce the intensity of follicular and dermal inflammation even when infection is not the main driver. In more severe or resistant disease, combinations such as clindamycin and rifampin may be used. This combination may reduce bacterial load and also alter the inflammatory environment within affected skin, helping to break the cycle of recurrent abscess formation.
Hormonal therapies are used in some patients, particularly when disease appears to fluctuate with androgen-sensitive physiology. Agents such as combined oral contraceptives, spironolactone, or other antiandrogen approaches may reduce the influence of androgens on sebaceous and follicular activity. Since hidradenitis suppurativa involves abnormal follicular occlusion and inflammation, decreasing androgen-mediated follicular stimulation can lower lesion formation in susceptible individuals. These therapies are most relevant when endocrine factors appear to contribute to disease activity.
Biologic therapies are used for moderate to severe hidradenitis suppurativa, especially when inflammation is widespread or when conventional antibiotics have not controlled the disease. The best established biologic treatment is adalimumab, a monoclonal antibody that blocks tumor necrosis factor alpha, a key inflammatory cytokine involved in recruitment and activation of immune cells. By reducing this signaling pathway, adalimumab decreases the chronic inflammatory response that maintains nodules and abscesses. Other biologics that target related inflammatory mediators may be considered in selected cases, particularly when the disease remains active despite standard therapy. These drugs are aimed at the immune dysregulation underlying the condition rather than at secondary bacterial colonization.
Systemic corticosteroids may be used for short periods in severe flares because they broadly suppress inflammatory gene expression and immune cell activation. They can reduce swelling and pain quickly, but they are usually not a long-term solution because prolonged suppression of the immune system can create other problems and because the disease often returns when the medication is withdrawn. Their role is mainly to interrupt a severe inflammatory episode.
Procedures or Interventions
Procedures are used when lesions have formed abscesses, sinus tracts, or fibrotic tissue that cannot be fully managed with medication alone. Incision and drainage can temporarily relieve pressure in a tense abscess by releasing trapped purulent material. This reduces pain and local tissue pressure, but it does not remove the diseased follicular unit or the chronically inflamed tract lining, so recurrence is common. For that reason, it is usually a short-term measure rather than a definitive treatment.
Laser therapies may be used to reduce hair follicles or modify diseased tissue. Hair follicle destruction with certain laser systems can reduce the number of follicular units available to become blocked and inflamed. This matters because follicular occlusion is a central initiating event in hidradenitis suppurativa. In some cases, laser energy is also used to treat active tissue or reduce chronic lesions, helping to lower the mechanical and inflammatory burden in affected areas.
Deroofing is a targeted procedure used for persistent sinus tracts and localized chronic lesions. The roof of the tunnel is removed, exposing the tract so that it can heal from the base upward. This changes the local structure of the disease by eliminating the epithelialized channel that repeatedly accumulates debris and inflammatory material. Because the tract lining is one of the features that allows disease to persist, deroofing can be more effective than drainage for certain chronic lesions.
Wide local excision is used in advanced disease when extensive scarring, multiple interconnected tracts, or repeated lesions have caused irreversible structural change. In this procedure, the entire diseased area is removed, including involved skin and subcutaneous tissue. The biological rationale is straightforward: if the anatomic region has become a chronic reservoir of inflammation and tract formation, removing that tissue eliminates the substrate for recurrence in that area. Healing then depends on regrowth or closure of unaffected tissue, which may require reconstruction depending on the size and site of excision.
Supportive or Long-Term Management Approaches
Long-term management usually combines ongoing medical suppression of inflammation with monitoring for recurrence and progression. Hidradenitis suppurativa is a relapsing disease, so treatment is often adjusted over time based on lesion frequency, severity, and the appearance of new sinus tracts or scarring. Repeated assessment helps determine whether the inflammatory component is being controlled or whether the disease is shifting toward more fixed structural damage.
Supportive care also includes measures that reduce friction, moisture, and mechanical stress in affected skin folds. These factors do not cause the disease by themselves, but they can aggravate follicular rupture and local inflammation in already susceptible skin. Reducing friction can therefore decrease the mechanical triggers that promote lesion formation. Similarly, management of obesity, smoking, and metabolic comorbidities may influence disease activity through effects on systemic inflammation, insulin signaling, and tissue oxygenation. These associations help explain why hidradenitis suppurativa often behaves as a disorder involving both local follicular pathology and broader inflammatory susceptibility.
Follow-up care is also used to monitor complications such as chronic drainage, secondary bacterial infection, anemia of inflammation in severe cases, and reduced mobility when lesions affect the groin or axillae. Ongoing care helps identify when a change in treatment is needed, especially if inflammatory control is incomplete or if the disease has progressed to a stage where procedural intervention is more appropriate than medication alone.
Factors That Influence Treatment Choices
Severity is one of the most important determinants of treatment. Mild disease with occasional nodules may respond to topical agents or limited oral therapy, while more extensive disease with recurrent abscesses or sinus tracts often requires systemic treatment and possibly surgery. Severity reflects how deeply inflammation has penetrated and how much tissue architecture has already been altered.
Stage of disease also matters. Early inflammatory lesions are more likely to respond to therapies that suppress follicular inflammation and immune activation. Once tunnels and scarring are established, treatment must address the physical persistence of diseased tissue. This is why medications that reduce cytokine signaling may be less effective on their own in late-stage disease.
Age, sex, hormonal status, and other health conditions can influence the choice of therapy. Hormonal treatments are more relevant when endocrine factors are contributing to follicular activity. Biologic agents may be selected cautiously when infections, liver disease, or other immune-related conditions affect risk. The presence of obesity, diabetes, inflammatory bowel disease, or polycystic ovary syndrome can also shape treatment choices because these conditions may modify systemic inflammation or affect the safety and effectiveness of certain drugs.
Previous treatment response is another major factor. If a patient improves with antibiotics, clinicians may continue using agents with anti-inflammatory and antimicrobial effects. If inflammation persists despite adequate medical therapy, escalation to biologics or procedural treatment suggests that the disease is being driven by immune activity or fixed anatomic lesions that require a different approach. Treatment is therefore often stepped up or shifted based on how the disease biology is behaving over time.
Potential Risks or Limitations of Treatment
Medical therapies have limitations because they rarely eliminate the underlying predisposition entirely. Antibiotics may suppress inflammation and bacterial overgrowth, but symptoms can recur when treatment stops. Long-term use can also select for resistant organisms and alter the skin and gut microbiome. Hormonal agents can affect blood pressure, potassium balance, menstrual patterns, or thrombotic risk depending on the medication used. Biologics can increase susceptibility to certain infections because they blunt specific immune pathways that are active in host defense as well as in inflammation.
Procedural treatments also have drawbacks. Incision and drainage can provide immediate relief, but because it does not remove the diseased follicular unit or tract lining, the underlying lesion often returns. Deroofing and excision are more definitive, but they involve wound healing, scarring, and possible recurrence at the edges of treated tissue if residual disease remains. Surgery in areas subject to moisture and friction can be challenging because these conditions affect healing and may prolong recovery.
Another limitation is that hidradenitis suppurativa often involves disease beyond what is visible on the skin surface. Microscopic inflammation can extend into surrounding tissue, which helps explain why seemingly successful treatment of one lesion does not always prevent new lesions nearby. Because the disease process is multifocal and chronic, treatment usually controls activity rather than curing the underlying tendency completely.
Conclusion
Hidradenitis suppurativa is treated with a layered approach that reflects the disease’s inflammatory and structural biology. Topical and oral antibiotics help reduce local inflammation and microbial amplification. Hormonal therapies modify follicular stimulation in selected patients. Biologics suppress immune pathways that drive chronic inflammation. Procedures such as deroofing, laser therapy, and excision address the persistent tissue changes created by repeated follicular rupture and scarring. Supportive long-term management helps limit mechanical and systemic factors that worsen disease activity. Across all stages, treatment is chosen to reduce symptoms, prevent progression, and counter the biological processes that keep the condition active.